Featured
Featured Videos
Bioprocessing in Boston: GEN Reports Live from BPI 2024
- Seres Therapeutics, developer of the first microbiome therapy platform
- Ring Therapeutics, a developer of gene therapies based on its commensal virome platform
- Cellarity, which aims to design medicines targeting the full cellular and molecular complexity of disease as opposed to a single molecular target
- Abiologics, a developer of programmable medicines combining generative artificial intelligence and high throughput chemical protein synthesis (it emerged from stealth mode in July)
- Cygnal Therapeutics, now part of Sonata Therapeutics, whose Network Medicines™ reprogram diseased cells to become “coordinators of cure” by releasing a defined array of signals designed to precisely coordinate multicellular networks to drive disease resolution
Avak Kahvejian, PhD, Recounts His Journey from Sequencing Pioneer to Flagship General Partner on “Close to the Edge”
This issue of GEN highlights “points of intervention.” The phrase usually refers to specific functions in a human institution that can be modified to improve the institution’s overall effectiveness. (For example, a business might revamp its production technology to boost profits.) But there are also points of intervention in biological systems, such as our aging bodies. In our cover story, we explore how epigenetic, bioelectromic, synaptic, and senolytic interventions could slow or even reverse aging. Other articles discuss points of intervention relevant to processes such as vaccine development and AI-driven drug design. (Incidentally, institutions that investigate such points of intervention are highlighted in this month’s A-List, which ranks the top 50 recipients of NIH funding.) And finally, bringing our “points” discussion full circle, we have an article on Biopharma 5.0, which describes the interventions that are blurring the lines between the digital, biological, commercial, and social spheres.